Oculis In-Person R&D Day: OCS-01 in Diabetic Macular Edema and OCS-02 in Dry Eye Disease
| DATE: | February 28, 2024 |
|---|---|
| TIME: | 9:00 AM EST |
| LOCATION: | InterContinental New York Barclay, 111 E 48th St, New York, NY 10017 |
About The Event
Join Oculis in-person or virtually for an R&D Day, featuring multiple ophthalmology experts who will showcase two of Oculis’ clinical programs:
OCS-01, a topical Optireach® formulation of Dexamethasone designed to reach the retina, in Diabetic Macular Edema (DME): Presentations will include an update on the OCS-01 development programs and a discussion of how OCS-01 could transform the current treatment paradigm by addressing the pre-invasive patient segment with an early intervention, and the segment of patients with inadequate response to current standard of care, from:
- David Boyer, M.D. (Keck School of Medicine, University of Southern California, and Retina Vitreous Associates Medical Group)
- Arshad M. Khanani, M.D., M.A. FASRS (Reno School of Medicine, University of Nevada, and Sierra Eye Associates)
- Ramin Tadayoni, M.D., Ph.D. (Université Paris Cité, Lariboisière & Rothschild Foundation Hospitals, Paris, President of EURETINA)
- Elizabeth Yeu, M.D. (Eastern Virginia Medical School, Virginia Eye Consultants, and President of ASCRS)
OCS-02, a TNFα inhibitor Licaminlimab eye drop formulation developed with a proprietary antibody fragment technology to treat ocular inflammation, in Dry Eye Disease (DED): Presentations will cover the unmet medical need, TNF inhibition mechanism of action to manage ocular inflammation, the potential for a precision medicine approach in DED, and an overview of the Licaminlimab (OCS-02) RELIEF trial program, from:
- Christophe Baudouin, M.D. Ph.D. (Quinze-Vingts National Ophthalmology Hospital, Paris)
- Eric Donnenfeld, M.D. (New York University)
- Anat Galor, M.D., M.S.P.H. (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami)
- George Ousler, M.S. (Ora, Inc.)
- Victor Perez, M.D. (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami)
The topic discussions will be moderated by Pravin Dugel, M.D. (Director, Oculis’ Board) and Riad Sherif, M.D. (Chief Executive Officer, Oculis).
In addition, management will provide a brief 2023 review and business outlook for 2024. Live question and answer sessions will be conducted during the event.